OCUGEN, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
OCUGEN, INC. (OCGN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- OCUGEN, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.88M, a 1.95% increase year-over-year.
- OCUGEN, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.06M, a 9.34% increase year-over-year.
- OCUGEN, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.98M, a 4.44% increase year-over-year.
- OCUGEN, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.84M, a 2.85% decline year-over-year.
- OCUGEN, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $7.71M, a 3.77% increase from fiscal 2024.
- OCUGEN, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $7.43M, a 19.42% decline from fiscal 2023.
- OCUGEN, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $9.22M, a 12.56% decline from fiscal 2022.
- OCUGEN, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $10.54M, a 51.49% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.88M 10-Q · filed 2026-08-06 | $3.94M derived: sum of 2 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $2.06M 10-Q · filed 2026-08-06 | |||||
| 2025-12-31 | $7.71M 10-K · filed 2026-03-04 | |||||
| 2025-09-30 | $1.98M 10-Q · filed 2025-11-05 | $3.82M derived: sum of 2 quarters · filed 2026-08-06 | $5.71M derived: sum of 3 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $1.84M 10-Q · filed 2026-08-06 | $3.73M derived: sum of 2 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $1.89M 10-Q · filed 2026-08-06 | |||||
| 2024-12-31 | $7.43M 10-K · filed 2026-03-04 | |||||
| 2024-09-30 | $1.89M 10-Q · filed 2025-11-05 | $3.79M derived: sum of 2 quarters · filed 2025-11-05 | $5.55M derived: sum of 3 quarters · filed 2025-11-05 | |||
| 2024-06-30 | $1.90M 10-Q · filed 2025-11-05 | $3.66M derived: sum of 2 quarters · filed 2025-11-05 | ||||
| 2024-03-31 | $1.76M 10-Q · filed 2025-11-05 | |||||
| 2023-12-31 | $9.22M 10-K · filed 2025-03-05 | |||||
| 2023-09-30 | $2.17M 10-Q · filed 2024-11-14 | $4.81M derived: sum of 2 quarters · filed 2024-11-14 | $7.50M derived: sum of 3 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $2.63M 10-Q · filed 2024-11-14 | $5.32M derived: sum of 2 quarters · filed 2024-11-14 | ||||
| 2023-03-31 | $2.69M 10-Q · filed 2024-11-14 | |||||
| 2022-12-31 | $10.54M 10-K · filed 2024-04-16 | |||||
| 2022-09-30 | $2.50M 10-K · filed 2024-04-16 | $4.57M derived: sum of 2 quarters · filed 2024-04-16 | $7.87M derived: sum of 3 quarters · filed 2024-04-16 | |||
| 2022-06-30 | $2.08M 10-K · filed 2024-04-16 | $5.38M derived: sum of 2 quarters · filed 2024-04-16 | ||||
| 2022-03-31 | $3.30M 10-K · filed 2024-04-16 | |||||
| 2021-12-31 | $6.96M 10-K · filed 2023-02-28 | |||||
| 2021-09-30 | $1.35M 10-Q · filed 2022-11-08 | $3.44M derived: sum of 2 quarters · filed 2022-11-08 | $4.28M derived: sum of 3 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $2.10M 10-Q · filed 2022-11-08 | $2.93M derived: sum of 2 quarters · filed 2022-11-08 | ||||
| 2021-03-31 | $833.00K 10-Q · filed 2022-11-08 | |||||
| 2020-12-31 | $660.00K 10-K · filed 2022-02-28 | $660.32K 10-K · filed 2021-03-19 | ||||
| 2020-09-30 | $126.00K 10-Q · filed 2021-11-09 | $126.29K 10-Q · filed 2020-11-06 | $275.00K derived: sum of 2 quarters · filed 2021-11-09 | $497.00K derived: sum of 3 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $149.00K 10-Q · filed 2021-11-09 | $149.21K 10-Q · filed 2020-08-14 | $371.00K derived: sum of 2 quarters · filed 2021-11-09 | |||
| 2020-03-31 | $222.00K 10-Q · filed 2021-11-09 | $222.51K 10-Q · filed 2020-05-08 | ||||
| 2019-12-31 | $884.00K 10-K · filed 2022-02-28 | $884.09K 10-K · filed 2020-03-27 | ||||
| 2019-09-30 | $193.00K 10-Q · filed 2020-11-06 | $304.81K derived: sum of 2 quarters · filed 2020-11-06 | $720.01K derived: sum of 3 quarters · filed 2020-11-06 | |||
| 2019-06-30 | $111.81K 10-Q · filed 2020-11-06 | $37.00K 10-Q · filed 2019-08-09 | $527.01K derived: sum of 2 quarters · filed 2020-11-06 | |||
| 2019-03-31 | $415.20K 10-Q · filed 2020-11-06 | $107.00K 10-Q · filed 2019-05-15 | ||||
| 2018-12-31 | $1.07M 10-K · filed 2020-03-27 | $1.63M 10-K · filed 2019-03-22 | ||||
| 2018-09-30 | $226.22K 10-Q · filed 2019-11-12 | $487.40K derived: sum of 2 quarters · filed 2019-11-12 | $746.08K derived: sum of 3 quarters · filed 2019-11-12 | |||
| 2018-06-30 | $261.19K 10-Q · filed 2019-11-12 | $407.00K 10-Q · filed 2019-08-09 | $519.87K derived: sum of 2 quarters · filed 2019-11-12 | |||
| 2018-03-31 | $258.68K 10-Q · filed 2019-11-12 | $403.00K 10-Q · filed 2019-05-15 | ||||
| 2017-12-31 | $1.57M 10-K · filed 2019-03-22 | |||||
| 2016-12-31 | $1.55M 10-K · filed 2018-03-15 | |||||
| 2015-12-31 | $1.23M 10-K · filed 2017-03-16 | |||||
| 2014-12-31 | $547.00K 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |